Bright Biotech produces high-quality recombinant proteins for the life sciences and food sectors using advanced expression systems that ensure high purity and efficacy. The company provides affordable and reliable protein sources, enabling researchers and manufacturers to improve product development and research outcomes.
Funding
$6.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
FFounders
Product
Problem
Current methods of recombinant protein production often face challenges in scalability, sustainability, and safety, particularly for applications in cellular agriculture and regenerative medicine. Traditional bioreactor-based systems can be resource-intensive and may not meet the growing demand for affordable and high-quality growth factors.
Solution
Bright Biotech leverages plant chloroplasts as natural bioreactors to produce recombinant proteins, offering a scalable and sustainable alternative to conventional methods. By transforming chloroplasts, the company achieves high-yield protein expression with enhanced purity and efficacy. This innovative approach provides a cost-effective and reliable source of growth factors for cellular agriculture and regenerative medicine, supporting the development of cell-based products and therapies.
Target Audience
The primary target audience includes researchers and manufacturers in the life sciences and food sectors, specifically those involved in cellular agriculture and regenerative medicine.
Features
- Utilizes plant chloroplasts for recombinant protein expression, enhancing scalability and sustainability
- Produces high-quality growth factors for cellular agriculture and regenerative medicine applications
- Offers a cost-effective alternative to traditional bioreactor-based protein production
- Ensures high protein purity and efficacy through advanced expression systems